Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Cancer shared this article with you from Inoreader Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Via MedWorm Cancer & Oncology Research CONCLUSIONS: Our results demonstrated that enzalutamide was associated with higher PSA response rate compared to abiraterone in patients with mCRPC, and no significant difference was found between two groups in the overall AE. But enzalutamide use induced higher risk of the AE of fatigue. PMID: 33217255 [PubMed - as supplied by publisher] (Source: J Pharm Pharm Sci) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.